Two experimental breast cancer drugs showed promising results in a closely watched study designed to enable the accelerated approval of medication that addresses unmet medical need in the treatment of serious or life threatening conditions. The drugs include AbbVie Inc’s veliparib, a treatment for an especially aggressive type of breast cancer known as triple negative, for which there are few effective treatments, and Puma Biotechnology Inc.’s neratinib, designed to treat a different type of breast cancer known as Her2-positive. Both drugs were tested in an unconventional mid-stage trial involving patients with confirmed breast cancer whose disease is considered curable but ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.